Adherence with tobramycin inhaled solution and health care utilization

Becky A. Briesacher1, Alexandra L. Quittner2, Lisa Saiman3, Patricia Sacco4, Hassan Fouayzi5, Lynne M. Quittell3
1University of Massachusetts Medical School and Meyers Primary Care Institute, Worcester, MA, USA
2University of Miami, Department of Psychology, Coral Gables, FL, USA
3Columbia University, Department of Pediatrics, New York, NY, USA
4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
5Meyers Primary Care Institute, Worcester, MA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Cystic Fibrosis Foundation: Patient Registry: Annual Data Report 2007. 2008, Bethesda, MD

Accurso FJ: Pulmonary and Critical Care Updates: Update in Cystic Fibrosis 2007. Am J Respir Crit Care Med. 2008, 177: 1058-1061. 10.1164/rccm.200801-069UP.

Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL: A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006, 5: 177-185. 10.1016/j.jcf.2006.03.002.

DiMatteo MR: Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004, 42: 200-209. 10.1097/01.mlr.0000114908.90348.f9.

Quittner AL, Barker DH, Marciel KK, Grimley ME: Cystic fibrosis: A model for drug discovery and patient care. 2009, NY: Guilford Press, 4

Cystic Fibrosis Foundation: Patients Registry: 2005 Annual Data Report. 2006, Bethesda, MD: Cystic Fibrosis Foundation

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL: Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002, 34: 91-100. 10.1002/ppul.10127.

Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K: Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001, 138: 699-704. 10.1067/mpd.2001.112897.

Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al: Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007, 176: 957-969. 10.1164/rccm.200705-664OC.

Zindani G, Streetman D, Streetman D, Nasr S: Adherence to treatment in children and adolescent patiens with cystic fibrosis. J Adolesc Health. 2006, 38: 13-17. 10.1016/j.jadohealth.2004.09.013.

Suri R, Wallis C, Bush A, et al: A comparitive study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technol Assess. 2002, 6: 1-60.

Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N: Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007, 132: 562-568. 10.1378/chest.06-2888.

Moskowitz S, Silva S, Mayer-Hamblett N, Pasta D, Mink D, Wagener S, Kostan M, Morgan W: Inhaled Antibiotic Use Among North American Cystic Fibrosis Patients. Annual Meeting of American Thorasic Society. 2007

Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D: Cystic fibrosis adult care: consensus conference report. Chest. 2004, 125: 1S-39S. 10.1378/chest.125.1_suppl.1S.

Adamson D, Chang S, Hansen L: Health research data for the real world: The MarketScan databases, in White Paper. 2005, Ann Arbor, MI: Thomson Medstat

MarketScan Research Databases User Guide and Database Dictionary. 2006, Ann Arbor, MI: Thomson Medstat

Rector TS, Wickstrom SL, Shah M, Thomas Greeenlee N, Rheault P, Rogowski J, Freedman V, Adams J, Escarce JJ: Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res. 2004, 39: 1839-1857. 10.1111/j.1475-6773.2004.00321.x.

Consumer Price Indexes. [ http://www.bls.gov/cpi/ ]

Ash A, Ellis RP, Pope G, Ayanian J, Bates D, Burstin H, Iezzoni L, McKay E, Yu W: Using Diagnoses to Describe Populations and Predict Costs. Health Care Financ Rev. 2000, 21: 7-28.

Petersen LA, Pietz K, Woodard LD, Byrne M: Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes. Med Care. 2005, 43: 61-67.

Briesacher BA, Sacco P, Fouayzi H, Quittner A: Tobramycin inhaled solution utilization in cystic fibrosis patients in a privately insured US population. 2009, Toronto

Cystic Fibrosis Foundation: Patient Registry 2001 and 2006 Annual Data Report. 2007, Bethesda, MA

Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS: Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology. 2008, 43: 874-881. 10.1002/ppul.20873.

Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999, 340: 23-30. 10.1056/NEJM199901073400104.

Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R: Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999, 37: 846-857. 10.1097/00005650-199909000-00002.

McNamara PS, McCormack P, McDonald AJ, Heaf L, Southern KW: Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros. 2009, 8: 258-263. 10.1016/j.jcf.2009.04.006.